NCT04204837 - Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 6, 2017

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Squamous Cell Carcinoma of the Skin

Interventions

DRUG

Nivolumab

Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.

DRUG

Nivolumab plus Relatlimab

Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit

Trial Locations (7)

1090

RECRUITING

Med Uni Wien, Univ. Klinik für Dermatologie, Vienna

3100

RECRUITING

Abteilung für Haut- und Geschlechtskrankheiten, Universitätsklinikum St. Pölten Karl Landsteiner Privatuniversität für Gesundheitswissenschaften, Sankt Pölten

4600

RECRUITING

Klinikum Wels-Grieskirchen GmbH, Wels

5020

RECRUITING

Universitätsklinik für Dermatologie und Allergologie der Paracelsus medizinischen Privatuniversität Salzburg, Salzburg

6020

RECRUITING

LKH Innsbruck Universitätsklinik für Dermatologie und Venerologie, Innsbruck

8020

RECRUITING

Universitätsklinikum Graz - LKH, Klinische Abteilung für Onkologie, Graz

9020

COMPLETED

Klinikum Klagenfurt am Wörthersee, Klagenfurt